Targeting IGF2BP2 effectively overcomes anti-EGFR-resistance mediated by either intracellular PI3K/AKT signaling hyperactivation or CAF-mediated tumor microenvironment interactions. This evidence concerns the gene IGF2BP2 and neoplasm.